Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) (KIDCARES10)
A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)
Sponsor: Kedrion S.p.A.
A PHASE3 clinical study on Primary Immunodeficiency Disease, this trial is ongoing. The trial is conducted by Kedrion S.p.A. and has accumulated 12 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Sep 2025 [monthly]
Recruiting PHASE3
-
Oct 2024 — Dec 2024 [monthly]
Recruiting PHASE3
▶ Show 7 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE3
-
Jul 2023 — May 2024 [monthly]
Recruiting PHASE3
-
May 2023 — Jul 2023 [monthly]
Recruiting PHASE3
-
Sep 2021 — May 2023 [monthly]
Recruiting PHASE3
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kedrion S.p.A.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bratislava, Slovakia , Brescia, Italy , Budapest, Hungary , Centennial, United States , Durham, United States , Florence, Italy , Genova, Italy , Lafayette, United States , Lisbon, Portugal , Milan, Italy and 9 more locations